interested to see if the NMR drug discovery program goes down the path of identifying an ALKBH5 inhibitor. aLkBH5 knockdown appears to increase cardiotoxicity the same as an FTO inhibitor.
Or perhaps a non-cytotoxic FTO / ALKBH5 inhibitor for other metabolic disorders?
[INTERVIEW] Breaking Barriers in Cancer Treatment: Race Oncology Pioneers a New Era with Bisantrene, page-52
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.045(2.80%) |
Mkt cap ! $272.6M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.55 | $414.6K | 257.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1400 | $1.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 1100 | 1 |
View Market Depth
| Last trade - 11.34am 30/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |